UBS Group
BIOR

UBS Group’s Biora Therapeutics, Inc. Common Stock BIOR Stock Holding History

UBS Group’s Portfolio BIOR Stock Details BIOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Hold
0
– -$1 – 10517
2024
Q2 		– Hold
0
– – – 9451
2024
Q1 		– Sell
-615
Closed -$8.3K – 10458
2023
Q4 		$8.3K Buy
+615
New +$9.97K ﹤0.01% 7568
2023
Q3 		– Sell
-185
Closed -$7.11K – 10377
2023
Q2 		$7.11K Buy
+185
New +$6.53K ﹤0.01% 7321
2023
Q1 		– Hold
0
– -$3 – 11542
2022
Q4 		– Hold
0
– – – 10643
2022
Q3 		– Sell
-4
Closed -$720 – 11506
2022
Q2 		$1K Buy
+4
New +$843 ﹤0.01% 10149
2021
Q4 		– Sell
-62
Closed -$24K – 11095
2021
Q3 		$24K Buy
62
+35
+130% +$15K ﹤0.01% 6994
2021
Q2 		$24K Sell
27
-27
-50% -$20.6K ﹤0.01% 7171
2021
Q1 		$65K Sell
54
-9
-14% -$12.4K ﹤0.01% 6302
2020
Q4 		$84K Buy
63
+56
+800% +$82.1K ﹤0.01% 5804
2020
Q3 		$16K Buy
+7
New +$15.8K ﹤0.01% 6493

Other funds holding BIOR

ACM
Athyrium Capital Management New York $8.69M AUM 34.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group's BIOR Position: Q3 2024 in Review

UBS Group held its Biora Therapeutics, Inc. Common Stock (BIOR) position steady in Q3 2024 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #10517.

UBS Group first reported a position in BIOR in Q3 2020 and has held it in 8 quarters since. The position peaked at $84K in Q4 2020. 20 funds tracked by Wall St. Rank hold BIOR as of Q3 2024.

  • UBS Group held 0 shares of Biora Therapeutics, Inc. Common Stock worth $0 as of Q3 2024.
  • UBS Group left its Biora Therapeutics, Inc. Common Stock share count unchanged in Q3 2024.
  • Biora Therapeutics, Inc. Common Stock made up ﹤0.01% of UBS Group's portfolio in Q3 2024, its #10517 holding.
  • UBS Group first reported a position in Biora Therapeutics, Inc. Common Stock in Q3 2020 and has held it in 8 quarters since.
  • UBS Group's Biora Therapeutics, Inc. Common Stock position peaked at $84K in Q4 2020.
  • 20 funds tracked by Wall St. Rank held Biora Therapeutics, Inc. Common Stock as of Q3 2024.

Based on UBS Group's 13F filing for Q3 2024, filed 14 Nov 2024.